SPOTLIGHT -
EP. 1: Clinical and Biological Distinctions in Neuroendocrine Tumors
EP. 2: Disease Factors Influencing Initial Treatment Approaches in NETs
EP. 3: Determining Surgical Candidacy in NETs
EP. 4: Symptom Management in Functional NETs
EP. 5: Goals of Therapy with Somatostatin Analogs in NETs
EP. 6: The Role of Surgery in the Management of NETs
EP. 7: Anti-Angiogenesis and mTOR Inhibition in Carcinoid Tumors
EP. 8: Chemotherapy Options in Neuroendocrine Tumors
EP. 9: Peptide Receptor Radionuclide Therapy in NETs
EP. 10: Sequencing Decisions in Neuroendocrine Tumors
EP. 11: Management of Obstruction-Related Symptoms for NETs
EP. 12: Systemic Treatment Options and Sequencing in pNETs
EP. 13: The Potential for Combination Therapy in Neuroendocrine Tumors
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
